ArticleFrontiers in immunology2025
Attenuation of IFITM proteins' antiviral activity through sequestration into intraluminal vesicles of late endosomes.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Atlastin-2-mediated endoplasmic reticulum membrane tethering is critical for flavivirus replication.PLoS biology · 2026Article
- Interferon-induced transmembrane (IFITM) proteins at the tumour-immune interface: A four-axis framework for their context-dependent roles.Clinical and translational medicine · 2026Review
- Interferon-induced transmembrane proteins in cancer and virus biology: a membrane perspective.mBio · 2026Review
- Cyclosporine A rescues the influenza virus fusion with IFITM3-expressing cells by relocating the restriction factor to intraluminal vesicles of multivesicular bodies.Journal of virology · 2026Article
- Divergent HIV-1 Restriction Phenotypes of IFITMs Expressed in Target Cells and Incorporated into Virions.Biomolecules · 2026Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
Introduction: Interferon-induced transmembrane proteins (IFITMs) inhibit the entry of diverse enveloped viruses. The spectrum of antiviral activity of IFITMs is largely determined by their subcellular localization. IFITM1 localizes to and primarily blocks viral fusion at the plasma membrane, while IFITM3 prevents viral fusion in late endosomes by accumulating in these compartments. We and others have previously shown that cyclosporine treatment relieves the fusion block for the Influenza A virus, but the mechanism of this rescue remained unclear. Results: Here, we report the existence of at least two distinct pools of IFITMs in cyclosporine treated cells. Major pools of IFITM1 and IFITM3 were found in endosomes, with IFITM1 relocating from the plasma membrane by a mechanism involving macropinocytosis, while the newly synthesized IFITMs were trapped in the Golgi. We noted that cyclosporine-mediated IFITM redistribution to late endosomes was not associated with its degradation. Importantly, cyclosporine treatment restricted antibody access to the cytoplasmic N-terminus but not to the extracellular C-terminus of IFITMs, consistent with IFITM sequestration in intraluminal vesicles of late endosomes. Indeed, super-resolution microscopy revealed that cyclosporine induces IFITM3 redistribution from the periphery to the interior of late endosomes. Discussion: Together, our results imply that IFITMs relocate to intraluminal vesicles of late endosomes in the presence of cyclosporine, thereby enabling viral fusion with the limiting membrane of these compartments. Our findings highlight the critical role of IFITM trafficking in antiviral defense and suggest a novel mechanism through which cyclosporine modulates the cell's susceptibility to viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.